Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

    ... architectures specifically upon treatment with lenalidomide and other drugs. Despite initial clinical response to ...

    Research Article last updated 07/18/2016 - 11:18am.

  2. Myelodysplastic syndromes: Contemporary review and how we treat

    ... (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, allogeneic stem ...

    Research Article last updated 04/29/2016 - 1:05pm.

  3. Personalized medicine for MDS

    ... treatment for MDS.  The classic example is the use of lenalidomide for patients with a del (5q) abnormality.  -In recent ... and the average length of response is 2 years.  -Lenalidomide works best in patients with red blood cell transfusion ...

    Research Review last updated 05/02/2016 - 9:44am.

  4. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

    ... et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or ... outcomes in these patients are needed. Azacitidine and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and ...

    Research Article last updated 06/28/2013 - 1:24pm.

  5. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... supportive care alone, cytotoxic therapy, lenalidomide , histone deacetylase inhibitors, and HSCT, favorable ...

    Research Article last updated 11/19/2015 - 8:32am.

  6. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    ... p53 expression status known to confer resistance to lenalidomide in low-risk del(5q) MDS might also influence response to ...

    Research Article last updated 07/07/2014 - 9:27am.

  7. How we treat lower risk myelodysplastic syndromes.

    ... while anemia of low risk MDS with del 5q responds to Lenalidomide in two thirds of the cases, but this drug should be used ... results have been reported with hypomethylating agents and lenalidomide. Selected patients respond to antithymocyte globulins, while ...

    Research Article last updated 05/14/2013 - 2:56pm.

  8. Current therapy of myelodysplastic syndromes.

    ... approval of azacitidine , decitabine , and lenalidomide in the last decade was a major breakthrough. Nonetheless, the ...

    Research Article last updated 09/03/2013 - 12:03pm.

  9. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... the US Food and Drug Administration for its treatment: lenalidomide , 5- azacitidine , and decitabine . These ...

    Research Article last updated 05/26/2015 - 12:13pm.

  10. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... of patients with MDS: immunomodulatory agents ( lenalidomide ), and hypomethylating therapy [HMT ( decitabine and ...

    Research Article last updated 05/12/2015 - 9:47am.